



ESMO Breast Cancer 2025 Industry Satellite Symposium

# Practical management of patients receiving inhibitors of the PI3K/AKT pathway



**Thursday 15 May 2025, 12:45–13:45 CEST**

Room 1, ICM – International Congress Center Messe München, Munich, Germany

Join us to discuss the practical aspects of treating patients with PI3K and AKT inhibitors to improve outcomes through accurate eligible patient identification and management of adverse events.

*We look forward to seeing you in Munich or via the live stream!*



**Prof. Peter Schmid**

*Barts Breast Cancer Centre,  
London, UK*



**Prof. Emanuele Bosi**

*Diabetes Research Institute at  
Ospedale San Raffaele, Milan, Italy*



**Prof. Shani Paluch-Shimon**

*Sharett Institute of Oncology  
Hadassah University Hospital,  
Jerusalem, Israel*

Welcome	Prof. Peter Schmid
Evolving landscape of PI3K/AKT inhibition	Prof. Shani Paluch-Shimon
Identifying patients who can benefit from PI3K/AKTis	Prof. Peter Schmid and Prof. Emanuele Bosi
Effective treatment management to maximise benefit	Prof. Emanuele Bosi and Prof. Peter Schmid
Q&A and discussion	All